ezh2 antibody  (NSJ Bioreagents)

Journal: BMC Cancer

Article Title: EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis

doi: 10.1186/s12885-025-15086-9

Figure Lengend Snippet: Elevated EZH2 expression correlates with poor prognosis in hepatocellular carcinoma (HCC). A Expression of EZH2 in the TCGA-HCC dataset, comparing HCC tissues with peri-tumoral liver tissues. B RT-qPCR assays demonstrating mRNA levels of EZH2 in 12 HCC patient samples and their corresponding adjacent normal tissues. C , D Western blot demonstrating protein levels of EZH2 in 12 HCC patient samples and their corresponding adjacent normal tissues. E Representative immunohistochemistry (IHC) images showing EZH2 expression in HCC tissues versus paired adjacent normal tissues. Statistical analysis comparing IHC scores of 12 HCC tissues with their paired normal tissues. F , G Kaplan-Meier overall survival curve and disease-free survival curve of HCC patients correlated with the expression of EZH2. All data are presented as the means ± SDs, n = 5 per group, * ( p < 0.05), ** ( p < 0.01), ns = no significance

Article Snippet: For immunostaining, tissue sections were incubated with a primary antibody targeting EZH2 (Cat# 21800-1-AP, Proteintech; working dilution 1:1000).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Immunohistochemistry

Journal: BMC Cancer

Article Title: EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis

doi: 10.1186/s12885-025-15086-9

Figure Lengend Snippet: EZH2 expression is increased in lenvatinib-resistant HCC cells and contributes to resistance development. A Schematic representation of the establishment of lenvatinib-resistant (LR) cells. B Cell viability assessed by CCK-8 assay following exposure to varying concentrations of lenvatinib for 48 h. Proliferation of both Huh7-LR and Hep3B-LR cells was greater than that of their parental cells at different lenvatinib concentrations. C , D mRNA and protein levels of EZH2 in Huh7-LR and Hep3B-LR cells, as well as their parental cells, detected by RT-PCR and western blot. E , F mRNA and protein levels of EZH2 in Huh7-LR and Hep3B-LR cells transfected with shEZH2#1, shEZH2#2, or shCtrl,, detected by RT-PCR and western blot. G , H Proliferation of both Huh7-LR and Hep3B-LR cells transfected with shEZH2#1 compared to those transfected with shCtrl at varying concentrations of lenvatinib. All data are presented as the means ± SDs, n = 5 per group, * ( p < 0.05), ** ( p < 0.01), ns = no significance

Article Snippet: For immunostaining, tissue sections were incubated with a primary antibody targeting EZH2 (Cat# 21800-1-AP, Proteintech; working dilution 1:1000).

Techniques: Expressing, CCK-8 Assay, Reverse Transcription Polymerase Chain Reaction, Western Blot, Transfection

Journal: BMC Cancer

Article Title: EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis

doi: 10.1186/s12885-025-15086-9

Figure Lengend Snippet: EZH2 inhibits ferroptosis in HCC cells. A Analysis of cell death and apoptosis in Huh7-LR and Hep3B-LR cells after Lenvatinib (Lenv) treatment via Annexin V-FITC/PI staining. B Inhibitory ratio that was measured in Huh7-LR and Hep3B-LR using CCK-8 assay 24 h after treatment with Lenvatinib with or without Z-VAD-FMK, CQ, Nec-1 or Fer-1. C Proliferation of both Huh7-LR and Hep3B-LR cells transfected with shCtrl compared to those transfected with shEZH2#1 at varying concentrations of RSL3. D - F Relative levels of reactive oxygen species (ROS) (D), glutathione (GSH) ( E ), and malondialdehyde (MDA) ( F ) in Huh7-LR and Hep3B-LR cells transfected with shEZH2 #1 compared to shCtrl treated with Lenvatinib, RSL3 and Fer-1. (G-H) Intracellular lipid peroxidation and iron accumulation in Huh7-LR and Hep3B-LR cells transfected with shEZH2 #1 compared to shCtrl treated with Lenvatinib, RSL3 and Fer-1 were determined by C11-BODIPY and FerroOrange staining. All data are presented as the means ± SDs, n = 5 per group, * ( p < 0.05), ** ( p < 0.01), ns = no significance

Article Snippet: For immunostaining, tissue sections were incubated with a primary antibody targeting EZH2 (Cat# 21800-1-AP, Proteintech; working dilution 1:1000).

Techniques: Staining, CCK-8 Assay, Transfection

Journal: BMC Cancer

Article Title: EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis

doi: 10.1186/s12885-025-15086-9

Figure Lengend Snippet: EZH2 suppression induced ferroptosis via enhancing ACSL1 expression through H3K27me3. A , B RT-qPCR assays demonstrated mRNA levels of indicated genes in in Huh7-LR (left panel) and Hep3B-LR (right panel) cells transfected with shEZH2 compared to shCtrl. C , D Expression levels of EZH2 in Huh7-LR ( C ) and Hep3B-LR ( D ) cells transfected with shEZH2 compared to shCtrl, detected by western blot. (E)Pearson correlation analysis of TCGA dataset revealed a significant negative correlation between EZH2 and ACSL1 expression. (F)Proliferation of Huh7-LR and Hep3B-LR cells transfected with shEZH2 or shACSL1. G - I Relative levels of ROS ( G ), GSH ( H ), and MDA ( I ) in Huh7-LR and Hep3B-LR cells transfected with shEZH2 or shACSL1. J-K Intracellular lipid peroxidation and iron accumulation in Huh7-LR and Hep3B-LR cells transfected with shEZH2 or shACSL1 were determined by C11-BODIPY and FerroOrange staining. L The protein levels of EZH2 and H3K27me3 in Huh7-LR cells transfected with shEZH2 or shCtrl were determined by western blot. M The enrichments of EZH2 and H3K27me3 on promoters of ACSL1 were determined by ChIP assays. N The altered enrichments of EZH2 and H3K27me3 on promoters of ACSL1 after EZH2 downregulatiton were determined by ChIP-qPCR assay. Normal IgG served as a negative control. All data are presented as the means ± SDs, n = 5 per group, * ( p < 0.05), ** ( p < 0.01), ns = no significance

Article Snippet: For immunostaining, tissue sections were incubated with a primary antibody targeting EZH2 (Cat# 21800-1-AP, Proteintech; working dilution 1:1000).

Techniques: Expressing, Quantitative RT-PCR, Transfection, Western Blot, Staining, ChIP-qPCR, Negative Control

Journal: BMC Cancer

Article Title: EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis

doi: 10.1186/s12885-025-15086-9

Figure Lengend Snippet: EZH2 reduction enhances lenvatinib efficacy in treating resistant HCC in vivo. A Treatment schedule illustrating the timing of tumor inoculation and administration of treatments in BALB/c nude mice ( n = 6 per group). B , C Representative images of tumors ( B ) harvested on day 27 posttreatment, and corresponding average tumor weights ( C ) in each group. D Tumor growth curves representing the progression of Huh7-LR cell-induced tumors in mice treated with lenvatinib. E Expression levels of EZH2, H3K27me3 and ACSL1 in tumors. All data are presented as the means ± SDs, n = 6 per group, * ( p < 0.05), ** ( p < 0.01), ns = no significance

Article Snippet: For immunostaining, tissue sections were incubated with a primary antibody targeting EZH2 (Cat# 21800-1-AP, Proteintech; working dilution 1:1000).

Techniques: In Vivo, Expressing

Journal: BMC Cancer

Article Title: EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis

doi: 10.1186/s12885-025-15086-9

Figure Lengend Snippet: Inhibition of EZH2 enhances lenvatinib efficacy in treating hepatocellular carcinoma by promoting ACSL1-Mediated Ferroptosis via H3K27me3

Article Snippet: For immunostaining, tissue sections were incubated with a primary antibody targeting EZH2 (Cat# 21800-1-AP, Proteintech; working dilution 1:1000).

Techniques: Inhibition